The U.S. weight-loss category has been rewritten. Ozempic, Wegovy, Mounjaro, and Zepbound — the GLP-1 receptor agonists — moved from diabetes drugs to the dominant weight-loss product in the country in under four years. WW International, formerly Weight Watchers, filed for Chapter 11 bankruptcy protection on May 6, 2025, cutting roughly $1.15 billion in debt. Jenny Craig shut its U.S. corporate operations in May 2023 and relaunched as a digital-only brand under new ownership. Nutrisystem's parent repositioned the brand around prescription telehealth. The commercial weight-loss category that existed when this piece was first written in January 2021 no longer exists.
How Big Is the GLP-1 Category, and Who Is Actually Taking These Drugs?
The most defensible public figure comes from KFF, whose polling found that roughly one in eight U.S. adults report having taken a GLP-1 medication — for weight loss, diabetes, or another condition — including about four in ten adults with diabetes and one in four with heart disease. That is a critical distinction most category marketing blurs: the one-in-eight figure covers all GLP-1 use, not weight-loss use alone. Gallup tracking through 2025 and 2026 has shown continued growth from that base.
Novo Nordisk and Eli Lilly built the two largest pharmaceutical franchises in the world on the back of it. The surrounding ecosystem — telehealth intake, compounded semaglutide, clinician networks, companion supplements, and side-effect management — grew alongside it. Any marketer citing a single headline dollar figure for "the weight-loss market" in 2026 is citing an estimate, not a measurement, and should say so. The honest framing is structural: the category is larger than it has ever been, and almost none of it looks like what it replaced.
Why Did the Hims & Hers Super Bowl Ad Work Commercially and Fail Politically?
The "Sick of the System" spot is the single most instructive marketing artifact in the category. It intercut junk-food imagery and obesity statistics with a pitch for the company's compounded GLP-1 offering at roughly $165 per month, against approximately $1,800 per month for branded Wegovy or Ozempic subscriptions. The disclosure that compounded medications are not FDA-approved appeared briefly, in small type.
The commercial result was unambiguous: 650%-plus traffic growth, a #2 app-store position in its category, and record new-customer registrations. The response was equally unambiguous:
- Novo Nordisk bought counter-advertising. On February 10, 2025 — the next day — it ran placements in The New York Times and USA Today warning that some compounded semaglutide vials "have been found to contain dangerous impurities, banned substances, or incorrect doses."
- Senators Dick Durbin (D-IL) and Roger Marshall (R-KS) wrote to the FDA on February 14, 2025, in a bipartisan letter accusing the company of misleading patients by omitting safety and side-effect information, and pledging legislation to close prescription-drug advertising gaps.
- The Obesity Society warned the ad would mislead viewers by excluding risk and side-effect information. PhRMA argued it violated the truthfulness requirements of the Federal Food, Drug, and Cosmetic Act.
- The Alliance for Pharmacy Compounding defended it — on the jurisdictional ground that advertising for compounded drugs falls under FTC authority rather than FDA prescription-drug rules.
That last point is the one communications leaders need to internalize, because it is the whole game.
What Is the Real Regulatory Constraint: FDA Rules or FTC Consumer Protection?
Branded prescription drugs advertise under FDA promotional rules — fair balance, risk disclosure, off-label restrictions. Compounded medications largely do not. They are not required to carry FDA-mandated labeling or risk-mitigation strategies, and their advertising sits under the Federal Trade Commission's general consumer-protection authority instead.
Marketers read that gap as freedom. It is not. It is a different regulator with different tools, and through 2025 and 2026 the FTC used them.
FTC v. NextMed. The Commission acted against the telehealth firm in July 2025 and approved a final consent order on December 3, 2025, by a 2-0 vote. The charges describe a marketing operation, not a medical one: undisclosed costs and membership commitments, unsubstantiated claims about client weight-loss results, fake testimonials, distorted consumer reviews, billing without informed consent, and unprocessed cancellation and refund requests. The order carries $150,000 for consumer refunds and, more consequentially, standing obligations — substantiate weight-loss outcome claims with competent and reliable evidence, do not misrepresent review authenticity, disclose material connections with endorsers, obtain express informed consent before billing, and provide simple cancellation.
Every one of those is a marketing-department control, not a clinical one.
FTC, Utah, and Los Angeles County v. Hims & Hers. On July 29, 2026, the FTC — joined by the State of Utah and Los Angeles County — filed in the Northern District of California. The complaint alleges the company shared sensitive consumer health information with third-party advertising platforms including Meta and Snap, through condition-segmented customer lists and site tracking technologies, while marketing itself on privacy. It further alleges consumers were charged immediately on intake-form submission despite messaging implying a consultation would come first, and that refill charges ran roughly ten days earlier than expected against a cancellation window closing two days prior. The claims are brought under Section 5 of the FTC Act and the Restore Online Shoppers' Confidence Act, which governs negative-option billing. No court findings have been entered; this is a developing matter.
Read the two together and the pattern is clear. The enforcement risk in this category attaches to the growth-marketing stack — the intake funnel, the subscription mechanics, the testimonial library, the retargeting pixel — not to the medicine.
How Did Novo Nordisk and Eli Lilly Take the Channel Back?
The manufacturers' answer to telehealth intermediaries was to become one. LillyDirect and NovoCare are direct-to-consumer channels that sell branded product to patients at published prices, collapsing the discount argument that compounders and telehealth resellers were built on. Both companies cut prices repeatedly through 2025 and 2026, including under pricing arrangements announced with the White House.
For marketers, this is a channel-control story with a communications consequence. When the manufacturer publishes a transparent direct price, the intermediary's core message — the same molecule for a fraction of the cost — loses its arithmetic. Positioning built on price arbitrage has a shelf life set by someone else's pricing decision.
Where Did the Legacy Weight-Loss Brands Actually Land?
WW International (WeightWatchers). Filed Chapter 11 on May 6, 2025, in a prepackaged plan that eliminated roughly $1.15 billion of debt, and emerged the same year with a smaller footprint oriented around GLP-1 patient support. Its own reporting has shown revenue from semaglutide prescriptions rising even as the subscriber base declined — the clearest single illustration of the category's transfer of value from program to prescription.
Nutrisystem. Repositioned around prescription GLP-1 telehealth. The celebrity-ambassador model that carried the brand for two decades — Marie Osmond, Dan Marino — has been retired in favor of clinical positioning.
Jenny Craig. Closed U.S. corporate operations in May 2023. Brand assets were acquired and relaunched as a digital-only program supporting members using GLP-1 medications.
Noom. Launched Noom Med in 2023, running prescription telehealth alongside its behavior-change platform to defend the subscriber base.
Each of the four became, in one form or another, a wrapper on the GLP-1 economy.
What Does the 2026 Weight-Loss Marketing Playbook Actually Require?
The tactics of the 2015–2020 category — celebrity ambassadors, before-and-after transformations, meal-plan influencer testimonials, month-to-month enrollment funnels — have not vanished. They have been demoted down the funnel and rebuilt around clinical authority and legal defensibility. Six requirements now define a competent program:
- Substantiation before creative. After NextMed, any outcome claim needs competent and reliable evidence on file before it runs. The testimonial library is now a legal exhibit.
- Endorser disclosure as standard practice. Material connections with endorsers must be disclosed. Influencer contracts in this category should be written to survive an FTC inquiry.
- Billing and cancellation as brand surfaces. ROSCA compliance is a marketing responsibility. The cancellation flow is a reputational asset or a complaint filed with a state attorney general.
- Data hygiene in the ad stack. The Hims complaint turns on pixels and condition-segmented audiences — decisions made by growth marketers. Health-adjacent retargeting is now a legal exposure, and a privacy-forward brand promise is a claim that will be tested against the tag manager.
- Clinician credibility over celebrity. Physician and dietitian credentialing at the top of the funnel, and earned media in the healthcare trade press — Endpoints, STAT News, Fierce Pharma, MedCity News — rather than lifestyle placement.
- AI-engine visibility as a primary channel. Buyers researching whether to try Ozempic or Wegovy, whether compounded semaglutide is safe, or which telehealth provider to use increasingly ask ChatGPT, Claude, Perplexity, Gemini, and Google AI Overviews before they reach any brand's website. Citation Share — the share of those answers a brand appears in — is now a category KPI, and AI Communications is how it gets built.
The Takeaway
The brands treating weight loss as a lifestyle category are losing to the brands treating it as a regulated healthcare category. Hims & Hers proved a Super Bowl buy can still move a health brand faster than anything else in marketing — 650% in a night — and then demonstrated, over the following eighteen months, exactly what that visibility attracts.
The operating question for a weight-loss marketer in 2026 is not which celebrity to sign. It is two questions: can every claim in the funnel survive an FTC substantiation demand, and what do the AI engines say when a buyer asks them first? That is where the category is now decided.
WW International filed Chapter 11 on May 6, 2025, in a prepackaged restructuring that eliminated roughly $1.15 billion in debt. The proximate cause was the collapse of its traditional membership model as GLP-1 medications displaced commercial diet programs. The company emerged the same year focused on GLP-1 patient support.
Are compounded GLP-1 drugs advertised under the same rules as Ozempic and Wegovy?
No, and this is the central regulatory fact in the category. Branded prescription drugs advertise under FDA promotional rules requiring fair balance and risk disclosure. Compounded medications are not FDA-approved and are not subject to those labeling requirements; their advertising falls under the FTC's general consumer-protection authority instead. Compounders remain subject to state pharmacy board oversight and USP standards.
What did the FTC's NextMed case establish for weight-loss marketers?
The final order, approved December 3, 2025, requires that weight-loss outcome claims be substantiated with competent and reliable evidence, prohibits misrepresenting review authenticity, requires disclosure of material connections with endorsers, and mandates express informed consent before billing plus a simple cancellation mechanism. It carried $150,000 for consumer refunds. The obligations, not the penalty, are the significant part.
How many Americans are taking GLP-1 drugs?
KFF polling found roughly one in eight U.S. adults report having taken a GLP-1 medication for any reason — weight loss, diabetes, or another condition — including about four in ten adults with diabetes. Figures attributing all GLP-1 use to weight loss overstate the weight-loss segment.
What is LillyDirect and why does it matter to marketers?
LillyDirect, and Novo Nordisk's NovoCare, are manufacturer-run direct-to-consumer channels selling branded product to patients at published prices. They matter because they erode the price-arbitrage positioning that telehealth and compounding intermediaries were built on. Messaging premised on being dramatically cheaper than the branded drug depends on a price the manufacturer controls.
Related Coverage
Sources
KFF GLP-1 polling · FTC press releases and case files, FTC v. NextMed (final order December 3, 2025) and FTC, Utah, and Los Angeles County v. Hims & Hers (filed July 29, 2026, N.D. Cal.) · WW International Chapter 11 filing and SEC disclosures, May 2025 · Fierce Healthcare and Marketing Brew reporting on Super Bowl LIX advertising · Novo Nordisk and Eli Lilly public pricing announcements.
